Yuxin Zhang

Dr. Yuxin Zhang

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Cancer Letters
Verified
Journal Article
Closed access
YZYuxin Zhang
Yuxin Zhang
YZYujie Zhang
Yujie Zhang
HTHaisu Tao
Haisu Tao
JZJinghan Zhu
Jinghan Zhu
YLYuanxiang Lu
Yuanxiang Lu
WZWanguang Zhang
Wanguang Zhang

28 December 2022 in Cells
Verified
Journal Article
Open access
PDF file
YZYujie Zhang
Yujie Zhang
YZYuxin Zhang
Yuxin Zhang
LPLin Peng Peng
Lin Peng Peng
LZLi Zhang
Li Zhang
Esophageal cancer is one of the malignant tumors with poor prognosis in China. Currently, the treatment of esophageal cancer is still based on surgery, especially in early and mid-stage patients, to achieve the goal of radical cure. However, esophageal cancer is a kind of tumor with a high risk of recurrence and metastasis, and locoregional recurrence and distant metastasis are the leading causes of death after surgery. Although multimodal comprehensive treatment has advanced in recent years, the prediction, prevention and treatment of postoperative recurrence and metastasis of esophageal cancer are still unsatisfactory. How to reduce recurrence and metastasis in patients after surgery remains an urgent problem to be solved. Given the clinical demand for early detection of postoperative recurrence of esophageal cancer, clinical and basic research aiming to meet this demand has been a hot topic, and progress has been observed in recent years. Therefore, this article reviews the research progress on the factors that influence and predict postoperative recurrence of esophageal cancer, hoping to provide new research directions and treatment strategies for clinical practice.

14 June 2022 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
JLJi Li
Ji Li
AWAn-Ran Wang
An-Ran Wang
XCXiao-Dong Chen
Xiao-Dong Chen
YZYuxin Zhang
Yuxin Zhang
HPHong Pan
Hong Pan
SLShi-Qiang Li
Shi-Qiang Li
Background: Peritoneal metastasis often occurs in patients with colorectal cancer peritoneal metastasis, and the prognosis is poor. A large body of evidence highlights the beneficial effects of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on survival, but to date, there is little consensus on the optimal treatment strategy for patients with colorectal cancer peritoneal metastasis. The purpose of this study is to evaluate the impact of CRS + HIPEC on survival and provide reference for the treatment of patients with colorectal cancer peritoneal metastasis. Methods: This systematic review and meta-analysis is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The PubMed, Embase, Cochrane, Web of Knowledge, and ClinicalTrials.gov databases were screened from inception of the review to March 11, 2022. Ten studies were included in qualitative and quantitative analysis. Results: A total of 3200 patients were enrolled in the study, including 788 patients in the CRS and HIPEC groups and 2412 patients in the control group, of which 3 were randomized controlled trials and 7 were cohort studies. The 3 randomized controlled studies were of high quality, and the quality scores of the 7 cohort studies were all 7 or above, indicating high quality. The results showed that the OS of CRS + HIPEC group was higher than that of control group (HR: 0.53, 95% CI: 0.38–0.73; P < 0.00001, I2 = 82.9%); the heterogeneity of the studies was large. The subgroup analysis showed that the OS of CRS and HIPEC group was higher than that of PC group (HR: 0.37, 95% CI: 0.30–0.47; P = 0.215, I2 = 31%) and higher than that in CRS group (HR: 0.73, 95% CI: 0.49–1.07; P = 0.163, I2 = 44.8%); the heterogeneity of the studies was low. In the OPEN group, the OS of THE CRS and HIPEC groups was higher than that in the control group (HR: 0.51, 95% CI: 0.38–0.70; P = 0.353, I2 = 3.9%); OPEN group showed lower heterogeneity. The OS of 60–100-min group was higher than that in the control group (HR: 0.65, 95% CI: 0.49–0.88; P = 0.172, I2 = 37.4%); the heterogeneity of the studies was low. Sensitivity analysis showed that there was no significant difference in the results of the combined analysis after each study was deleted. The results of publication bias showed that the P-value of Egger and Begg tests was 0.078 > 0.05, indicating that there is no publication bias. Conclusions: CRS + HIPEC can improve the survival rate of patients with colorectal cancer peritoneal metastasis

Verified
Journal Article
Open access
PDF file
YXYANG XING
YANG XING
KCKun Cheng
Kun Cheng
CCChen Chen
Chen Chen
YZYuxin Zhang
Yuxin Zhang
DWDaowen Wang
Daowen Wang
Metabolic dysfunction-associated steatotic liver disease (MASLD) and heart failure (HF) frequently coexist within a shared cardiometabolic environment, yet their mitochondrial abnormalities are stage- and phenotype-dependent rather than uniform. In MASLD, mitochondrial adaptation evolves from increased oxidative metabolism in early steatosis toward impaired respiratory flexibility, oxidative stress, and defective quality control with disease progression, whereas the failing myocardium develops reduced energetic reserve and altered substrate utilization. These organ-specific disturbances can modify mitochondria-linked metabolites, mitochondrial damage-associated molecular patterns, stress-responsive endocrine mediators, and extracellular vesicle-associated mitochondrial cargo. However, similar mitochondrial abnormalities or circulating signals in the liver and heart do not by themselves establish direct inter-organ communication. This review distinguishes shared systemic drivers and organ-intrinsic mitochondrial stress from source-resolved cardio-hepatic signaling, highlighting hepatic ketogenesis, fibroblast growth factor 21 (FGF21), mitochondrial DNA (mtDNA)-dependent inflammatory pathways, and extracellular vesicle-mediated cargo transfer as mechanistically distinct examples with different levels of evidence. We further discuss biomarker limitations, HF-related hemodynamic liver injury, and therapeutic strategies ranging from established cardiometabolic unloading to emerging mitochondria-centered interventions. A stage-, phenotype-, and source-resolved framework may improve interpretation of mitochondrial signals and guide future mechanistic and translational studies in the MASLD–HF overlap.

10 April 2023
Verified
Report
Open access
JLJi Li
Ji Li
CHChongqing Western District Hospital
Chongqing Western District Hospital
AWAn-Ran Wang
An-Ran Wang
SLShi-Qiang Li
Shi-Qiang Li
QXQing-Lin Xiang
Qing-Lin Xiang
YZYuxin Zhang
Yuxin Zhang
INPLASY202340030 Comparison of enteral immunonutrition and enteral nutrition in patients undergoing gastric cancer surgery:a systematic review and network meta-analysis of randomized controlled tri…

6 September 2023
Verified
Report
Open access
JLJi Li
Ji Li
CHChongqing Western District Hospital
Chongqing Western District Hospital
QXQing-Lin Xiang
Qing-Lin Xiang
SLShi-Qiang Li
Shi-Qiang Li
YZYuxin Zhang
Yuxin Zhang
JZJin-Xian Zhu
Jin-Xian Zhu
INPLASY202390019 Efficacy of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in advanced or metastatic colorectal cancer patients with metastatic microsatellite stable (MSS) o…